A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases

Journal of Ginseng Research

Volumn 38, Issue 3, 2014, Pages 161-166

  Lee, Chang Ho ^a   Kim, Jong Hoon ^b  

^a Hanyang University   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

Antioxidant effect; Cardiovascular diseases; Lipid profile; Myocardial protection; Vasomotor tone

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM CHANNEL; GINSENG EXTRACT; GINSENOSIDE; ION CHANNEL; LIPID;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG STRUCTURE; GINSENG; HEART DISEASE; HEART FUNCTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TRADITIONAL MEDICINE; VASOMOTOR REFLEX;

EID: 84904858695     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgr.2014.03.001     Document Type: Review

References (89)

1. Gielen S, Landmesser U. The Year in Cardiology 2013: cardiovascular disease prevention. Eur Heart J 2014;35:307-12.
2. Lim KH, Ko D, Kim JH. Cardioprotective potential of Korean Red Ginseng extract on isoproterenol-induced cardiac injury in rats. J Ginseng Res 2013;37:273-82.
3. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mähönen M, Cepaitis Z, Kuulasmaa K, Keil U. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000;355:688-700.
4. Toth PP. Making a case for quantitative assessment of cardiovascular risk. J Clin Lipidol 2007;1:234-41.
5. Libby P. Act local, act global: inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol 2005;45:1600-2.
6. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and Eselectin in human atherosclerosis. J Pathol 1993;171:223-9.
7. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-44.
8. Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 1997;54:1-8.
9. Buettner C, Yeh GY, Phillips RS, Mittleman MA, Kaptchuk TJ. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother 2006;40:83-95.
10. Lim KH, Lim DJ, Kim JH. Ginsenoside-Re ameliorates ischemia and reperfusion injury in the heart: a hemodynamics approach. J Ginseng Res 2013;37:283-92.
11. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-93.
12. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen CJ. Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit 2004;10:187-92.
13. Cheng Y, Shen LH, Zhang JT. Anti-amnestic and anti-aging effects of ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol Sin 2005;26:143-9.
14. Nah SY, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 2007;13:381-404.
15. Brekhman II, Dardymov IV. New substances of plant origin which increase nonspecific resistance. Annu Rev Pharmacol 1969;9:419-30.
16. Bittles AH, Fulder SJ, Grant EC, Nicholls MR. The effect of ginseng on lifespan and stress responses in mice. Gerontology 1979;25:125-31.
17. Zhou DH. Preventive geriatrics: an overview from traditional Chinese medicine. Am J Chin Med 1982;10:32-9.
18. Bolli R. Superoxide dismutase 10 years later: a drug in search of a use. J Am Coll Cardiol 1991;18:231-3.
19. Miller SC, Delorme D, Shan JJ. CVT-E002 stimulates the immune system and extends the life span of mice bearing a tumor of viral origin. J Soc Integr Oncol 2009;7:127-36.
20. Samukawa K, Suzuki Y, Ohkubo N, Aoto M, Sakanaka M, Mitsuda N. Protective effect of ginsenosides Rg(2) and Rh(1) on oxidation-induced impairment of erythrocyte membrane properties. Biorheology 2008;45:689-700.
21. Li XT, Chen R, Jin LM, Chen HY. Regulation on energy metabolism and protection on mitochondria of Panax ginseng polysaccharide. Am J Chin Med 2009;37:1139-52.
22. Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, Nagarkatti M, Windust A, Cui T. An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol 2010;130:222-30.
23. Sohn SH, Kim SK, Kim YO, Kim HD, Shin YS, Yang SO, Kim SY, Lee SW. A comparison of antioxidant activity of Korean White and Red Ginsengs on H2O2-induced oxidative stress in HepG2 hepatoma cells. J Ginseng Res 2013;37:442-50.
24. Chen X. Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Clin Exp Pharmacol Physiol 1996;23:728-32.
25. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Ginsenoside Rb1 blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2005;41:861-8.
26. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007;44:493-9.
27. Xie JT, Shao ZH, Vanden Hoek TL, Chang WT, Li J, Mehendale S, Wang CZ, Hsu CW, Becker LB, Yin JJ, et al. Antioxidant effects of ginsenoside Re in cardiomyocytes. Eur J Pharmacol 2006;532:201-7.
28. Deng HL, Zhang JT. Anti-lipid peroxilative effect of ginsenoside Rb1 and Rg1. Chin Med J (Engl) 1991;104:395-8.
29. Lü JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7:293-302.
30. He F, Guo R, Wu SL, Sun M, Li M. Protective effects of ginsenoside Rb1 on human umbilical vein endothelial cells in vitro. J Cardiovasc Pharmacol 2007;50:314-20.
31. Kim YM, Namkoong S, Yun YG, Hong HD, Lee YC, Ha KS, Lee H, Kwon HJ, Kwon YG, Kim YM. Water extract of Korean red ginseng stimulates angiogenesis by activating the Pi3k/Akt-dependent Erk1/2 and eNOS pathways in human umbilical vein endothelial cells. Biol Pharm Bull 2007;30:1674-9.
32. Leung KW, Yung KK, Mak NK, Yue PY, Luo HB, Cheng YK, Fan TP, Yeung HW, Ng TB, Wong RN. Angiomodulatory and neurological effects of ginsenosides. Curr Med Chem 2007;14:1371-80.
33. Nakaya Y, Mawatari K, Takahashi A, Harada N, Hata A, Yasui S. The phytoestrogen ginsensoside Re activates potassium channels of vascular smooth muscle cells through Pi3k/Akt and nitric oxide pathways. J Med Invest 2007;54:381-4.
34. Leung KW, Leung FP, Huang Y, Mak NK, Wong RN. Non-genomic effects of ginsenoside-Re in endothelial cells via glucocorticoid receptor. FEBS Lett 2007;581:2423-8.
35. Papapetropoulos A. A ginseng-derived oestrogen receptor beta (Erbeta) agonist, Rb1 ginsenoside, attenuates capillary morphogenesis. Br J Pharmacol 2007;152:172-4.
36. Lei Y, Gao Q, Chen KJ. Effects of extracts from Panax notoginseng and Panax ginseng fruit on vascular endothelial cell proliferation and migration in vitro. Chin J Integr Med 2008;14:37-41.
37. Hong SJ, Wan JB, Zhang Y, Hu G, Lin HC, Seto SW, Kwan YW, Lin ZX, Wang YT, Lee SM. Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. Phytother Res 2009;23:677-86.
38. Wan JB, Lee SM, Wang JD, Wang N, He CW, Wang YT, Kang JX. Panax notoginseng reduces atherosclerotic lesions in ApoE-deficient mice and inhibits TNF-alpha-induced endothelial adhesion molecule expression and monocyte adhesion. J Agric Food Chem 2009;57:6692-7.
39. Hien TT, Kim ND, Pokharel YR, Oh SJ, Lee MY, Kang KW. Ginsenoside Rg3 increases nitric oxide production via increases in phosphorylation and expression of endothelial nitric oxide synthase: essential roles of estrogen receptor-dependent Pi3-kinase and Amp-activated protein kinase. Toxicol Appl Pharmacol 2010;246:171-83.
40. Jeong A, Lee HJ, Jeong SJ, Lee HJ, Lee EO, Bae H, Kim SH. Compound K inhibits basic fibroblast growth factor-induced angiogenesis via regulation of P38 mitogen activated protein kinase and Akt in human umbilical vein endothelial cells. Biol Pharm Bull 2010;33:945-50.
41. Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J 1989;53:557-73.
42. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
43. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
44. Yu J, Eto M, Akishita M, Kaneko A, Ouchi Y, Okabe T. Signaling pathway of nitric oxide production induced by ginsenoside Rb1 in human aortic endothelial cells: a possible involvement of androgen receptor. Biochem Biophys Res Commun 2007;353:764-9.
45. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP, Wong RN. Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. FEBS Lett 2006;580:3211-6.
46. Kang YJ, Sohn JT, Chang KC. Relaxation of canine corporal smooth muscle relaxation by ginsenoside saponin Rg3 is independent from eNOS activation. Life Sci 2005;77:74-84.
47. Jovanovski E, Jenkins A, Dias AG, Peeva V, Sievenpiper J, Arnason JT, Rahelic D, Josse RG, Vuksan V. Effects of Korean red ginseng (Panax Ginseng C.A. Mayer) and its isolated ginsenosides and polysaccharides on arterial stiffness in healthy individuals. Am J Hypertens 2010;23:469-72.
48. Lee JY, Lim KM, Kim SY, Bae ON, Noh JY, Chung SM, Kim K, Shin YS, Lee MY, Chung JH. Vascular smooth muscle dysfunction and remodeling induced by ginsenoside Rg3, a bioactive component of ginseng. Toxicol Sci 2010;117:505-14.
49. Wang T, Yu XF, Qu SC, Xu HL, Sui DY. Ginsenoside Rb3 inhibits angiotensin IIinduced vascular smooth muscle cells proliferation. Basic Clin Pharmacol Toxicol 2010;107:685-9.
50. Rhee MY, Kim YS, Bae JH, Nah DY, Kim YK, Lee MM, Kim HY. Effect of Korean red ginseng on arterial stiffness in subjects with hypertension. J Altern Complement Med 2011;17:45-9.
51. Jeon BH, Kim CS, Park KS, Lee JW, Park JB, Kim KJ, Kim SH, Chang SJ, Nam KY. Effect of Korea red ginseng on the blood pressure in conscious hypertensive rats. Gen Pharmacol 2000;35:135-41.
52. Shin W, Yoon J, Oh GT, Ryoo S. Korean red ginseng inhibits arginase and contributes to endothelium-dependent vasorelaxation through endothelial nitric oxide synthase coupling. J Ginseng Res 2013;37:64-73.
53. Vuksan V, Stavro M, Woo M, Leiter LA, Sung MK, Sievenpiper JL. Korean red ginseng (Panax ginseng) can lower blood pressure in individuals with hypertension: a randomized controlled trial. In: Proceedings of the 9th International Ginseng Symposium. Geumsan: Korean Society of Ginseng; 2006, p. 35-6.
54. Baek EB, Yoo HY, Park SJ, Chung YS, Hong EK, Kim SJ. Inhibition of arterial myogenic responses by a mixed aqueous extract of Salvia miltiorrhiza and Panax notoginseng (PASEL) showing antihypertensive effects. Korean J Physiol Pharmacol 2009;13:287-93.
55. Wagner HN, Liu X. The international textbook of cardiology. New York: Pergamon Press; 1987.
56. Liu L, Shi R, Shi Q, Cheng Y, Huo Y. Protective effect of saponins from Panax notoginseng against doxorubicin-induced cardiotoxicity in mice. Planta Med 2008;74:203-9.
57. Qin N, Gong QH, Wei LW, Wu Q, Huang XN. Total ginsenosides inhibit the right ventricular hypertrophy induced by monocrotaline in rats. Biol Pharm Bull 2008;31:1530-5.
58. Deng J, Wang YW, Chen WM, Wu Q, Huang XN. Role of nitric oxide in ginsenoside Rg(1)-induced protection against left ventricular hypertrophy produced by abdominal aorta coarctation in rats. Biol Pharm Bull 2010;33:631-5.
59. Wang YG, Zima AV, Ji X, Pabbidi R, Blatter LA, Lipsius SL. Ginsenoside Re suppresses electromechanical alternans in cat and human cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295:H851-9.
60. Wang Z, Li M, Wu WK, Tan HM, Geng DF. Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction. Cardiovasc Drugs Ther 2008;22:443-52.
61. Deng J, Lv XT, Wu Q, Huang XN. Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings. Eur J Pharmacol 2009;608:42-7.
62. Wang YL, Wang CY, Zhang BJ, Zhang ZZ. Shenfu injection suppresses apoptosis by regulation of Bcl-2 and caspase-3 during hypoxia/reoxygenation in neonatal rat cardiomyocytes in vitro. Mol Biol Rep 2009;36:365-70.
63. Zhu D, Wu L, Li CR, Wang XW, Ma YJ, Zhong ZY, Zhao HB, Cui J, Xun SF, Huang XL, et al. Ginsenoside Rg1 protects rat cardiomyocyte from hypoxia/reoxygenation oxidative injury via antioxidant and intracellular calcium homeostasis. J Cell Biochem 2009;108:117-24.
64. Kim TH, Lee SM. The effects of ginseng total saponin, panaxadiol and panaxatriol on ischemia/reperfusion injury in isolated rat heart. Food Chem Toxicol 2010;48:1516-20.
65. Wu Y, Xia ZY, Dou J, Zhang L, Xu JJ, Zhao B, Lei S, Liu HM. Protective effect of ginsenoside Rb1 against myocardial ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Mol Biol Rep 2011;38:4327-35.
66. Bodiga S, Wang W, Oudit GY. Use of ginseng to reduce post-myocardial adverse myocardial remodeling: applying scientific principles to the use of herbal therapies. J Mol Med (Berl) 2011;89:317-20.
67. Guo J, Gan XT, Haist JV, Rajapurohitam V, Zeidan A, Faruq NS, Karmazyn M. Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation. Circ Heart Fail 2011;4:79-88.
68. Tsutsumi YM, Tsutsumi R, Mawatari K, Nakaya Y, Kinoshita M, Tanaka K, Oshita S, Compound K. a metabolite of ginsenosides, induces cardiac protection mediated nitric oxide via Akt/Pi3k pathway. Life Sci 2011;88:725-9.
69. Zhou H, Hou SZ, Luo P, Zeng B, Wang JR, Wong YF, Jiang ZH, Liu L. Ginseng protects rodent hearts from acute myocardial ischemia-reperfusion injury through GR/ER-activated risk pathway in an endothelial NOS-dependent mechanism. J Ethnopharmacol 2011;135:287-98.
70. Tamura Y. Effects of Korean red ginseng on eicosanoid biosynthesis in platelets and vascular smooth muscle cells. In: Proceedings of the 6th International Ginseng Symposium. Seoul: Korean Society of Ginseng; 1993. p. 28-9.
71. Dong-Ha Lee DH, Cho HJ, Kim HH, Rhee MH, Ryu JH, Park JH. Inhibitory effects of total saponin from Korean red ginseng via vasodilator-stimulated phosphoprotein-Ser157 phosphorylation on thrombin-induced platelet aggregation. J Ginseng Res 2013;37:176-86.
72. Jin YR, Yu JY, Lee JJ, You SH, Chung JH, Noh JY, Im JH, Han XH, Kim TJ, Shin KS, et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol 2007;100:170-5.
73. Lee WM, Kim SD, Park MH, Cho JY, Park HJ, Seo GS, Rhee MH. Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: critical roles of ERK2 and cAMP. J Pharm Pharmacol 2008;60:1531-6.
74. Li GX, Liu ZQ. The protective effects of ginsenosides on human erythrocytes against hemin-induced hemolysis. Food Chem Toxicol 2008;46:886-92.
75. Yang JY, Sun K, Wang CS, Guo J, Xue X, Liu YY, Zheng J, Fan JY, Liao FL, Han JY. Improving effect of post-treatment with Panax notoginseng saponins on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Clin Hemorheol Microcirc 2008;40:119-31.
76. Lee JG, Lee YY, Wu B, Kim SY, Lee YJ, Yun-Choi HS, Park JH. Inhibitory activity of ginsenosides isolated from processed ginseng on platelet aggregation. Pharmazie 2010;65:520-2.
77. Lee YH, Lee BK, Choi YJ, Yoon IK, Chang BC, Gwak HS. Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. Int J Cardiol 2010;145:275-6.
78. Yi XQ, Li T, Wang JR, Wong VK, Luo P, Wong IY, Jiang ZH, Liu L, Zhou H. Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling. Phytomedicine 2010;17:1006-15.
79. Ahn CM, Hong SJ, Choi SC, Park JH, Kim JS, Lim DS. Red ginseng extract improves coronary flow reserve and increases absolute numbers of various circulating angiogenic cells in patients with first ST-segment elevation acute myocardial infarction. Phytother Res 2011;25:239-49.
80. Trinh HT, Han SJ, Kim SW, Lee YC, Kim DH. Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J Microbiol Biotechnol 2007;17:1127-33.
81. Hwang SY, Son DJ, Kim IW, Kim DM, Sohn SH, Lee JJ, Kim SK. Korean red ginseng attenuates hypercholesterolemia-enhanced platelet aggregation through suppression of diacylglycerol liberation in high-cholesterol-diet-fed rabbits. Phytother Res 2008;22:778-83.
82. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, Liu YH, Li SH, Lian XM, Tang Z. Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin Exp Pharmacol Physiol 2008;35:1238-44.
83. Liu G, Wang B, Zhang J, Jiang H, Liu F. Total Panax notoginsenosides prevent atherosclerosis in apolipoprotein E-knockout mice: role of downregulation of CD40 and MMP-9 expression. J Ethnopharmacol 2009;126:350-4.
84. Jia Y, Li ZY, Zhang HG, Li HB, Liu Y, Li XH. Panax notoginseng saponins decrease cholesterol ester via up-regulating ATP-binding cassette transporter A1 in foam cells. J Ethnopharmacol 2010;132:297-302.
85. Kwak YS, Kyung JS, Kim JS, Cho JY, Rhee MH. Anti-hyperlipidemic effects of red ginseng acidic polysaccharide from Korean red ginseng. Biol Pharm Bull 2010;33:468-72.
86. Li J, Xie ZZ, Tang YB, Zhou JG, Guan YY. Ginsenoside-Rd, a purified component from Panax notoginseng saponins, prevents atherosclerosis in apoE knockout mice. Eur J Pharmacol 2011;652:104-10.
87. 2+ entry blocker, reverses basilar hypertrophic remodeling in stroke-prone renovascular hypertensive rats. Eur J Pharmacol 2009;606:142-9.
88. Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 2000;87:275-81.
89. +-ATPase activity. Acta Pharmacol Sin 2009;30:61-9.